Literature DB >> 27470603

Unexpected macrophage-independent dyserythropoiesis in Gaucher disease.

Nelly Reihani1, Jean-Benoit Arlet2, Michael Dussiot3, Thierry Billette de Villemeur4, Nadia Belmatoug5, Christian Rose6, Yves Colin-Aronovicz1, Olivier Hermine7, Caroline Le Van Kim1, Melanie Franco8.   

Abstract

Gaucher disease is a rare inherited disease caused by a deficiency in glucocerebrosidase leading to lipid accumulation in cells of mononuclear-macrophage lineage known as Gaucher cells. Visceral enlargement, bone involvement, mild anemia and thrombocytopenia are the major manifestations of Gaucher disease. We have previously demonstrated that the red blood cells from patients exhibit abnormal properties, which indicates a new role in Gaucher disease pathophysiology. To investigate whether erythroid progenitors are affected, we examined the in vitro erythropoiesis from the peripheral CD34+ cells of patients and controls. CD34- cells were differentiated into macrophages and co-cultivated with erythroblasts. We showed an accelerated differentiation of erythroid progenitors without maturation arrest from patients compared to controls. This abnormal differentiation persisted in the patients when the same experiments were performed without macrophages, which strongly suggested that dyserythropoiesis in Gaucher disease is secondary to an inherent defect in the erythroid progenitors. The accelerated differentiation was associated with reduced cell proliferation. As a result, less mature erythroid cells were generated in vitro in the Gaucher disease cultures compared to the control. We then compared the biological characteristics of untreated patients according to their anemic status. Compared to the non-anemic group, the anemic patients exhibit higher plasma levels of growth differentiation factor-15, a marker of ineffective erythropoiesis, but they had no indicators of hemolysis and similar reticulocyte counts. Taken together, these results demonstrated an unsuspected dyserythropoiesis that was independent of the macrophages and could participate, at least in part, to the basis of anemia in Gaucher disease. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27470603      PMCID: PMC5479608          DOI: 10.3324/haematol.2016.147546

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  42 in total

1.  Erythrophagocytosis in Gaucher cells.

Authors:  Asaf Bitton; Joan Etzell; James P Grenert; Endi Wang
Journal:  Arch Pathol Lab Med       Date:  2004-10       Impact factor: 5.534

2.  Introduction. Advances in Gaucher Disease: therapeutic goals and evaluation and monitoring guidelines.

Authors:  Neal J Weinreb
Journal:  Semin Hematol       Date:  2004-10       Impact factor: 3.851

3.  HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia.

Authors:  Jean-Benoît Arlet; Jean-Antoine Ribeil; Flavia Guillem; Olivier Negre; Adonis Hazoume; Guillaume Marcion; Yves Beuzard; Michaël Dussiot; Ivan Cruz Moura; Samuel Demarest; Isaure Chauvot de Beauchêne; Zakia Belaid-Choucair; Margaux Sevin; Thiago Trovati Maciel; Christian Auclair; Philippe Leboulch; Stany Chretien; Luba Tchertanov; Véronique Baudin-Creuza; Renaud Seigneuric; Michaela Fontenay; Carmen Garrido; Olivier Hermine; Geneviève Courtois
Journal:  Nature       Date:  2014-08-24       Impact factor: 49.962

4.  Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

Authors:  Aneal Khan; Thomas Hangartner; Neal J Weinreb; John S Taylor; Pramod K Mistry
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

5.  Purification, amplification and characterization of a population of human erythroid progenitors.

Authors:  J M Freyssinier; C Lecoq-Lafon; S Amsellem; F Picard; R Ducrocq; P Mayeux; C Lacombe; S Fichelson
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

6.  Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III.

Authors:  O Nilsson; G Håkansson; S Dreborg; C G Groth; L Svennerholm
Journal:  Clin Genet       Date:  1982-11       Impact factor: 4.438

7.  Sphingosine kinase 2 (Sphk2) regulates platelet biogenesis by providing intracellular sphingosine 1-phosphate (S1P).

Authors:  Lin Zhang; Nicole Urtz; Florian Gaertner; Kyle R Legate; Tobias Petzold; Michael Lorenz; Alexandra Mazharian; Steve P Watson; Steffen Massberg
Journal:  Blood       Date:  2013-06-17       Impact factor: 22.113

8.  Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts.

Authors:  Jean-Marie Ramirez; Olivier Schaad; Stephane Durual; Dominique Cossali; Mylène Docquier; Photis Beris; Patrick Descombes; Thomas Matthes
Journal:  Br J Haematol       Date:  2008-11-19       Impact factor: 6.998

Review 9.  Role of sphingosine 1-phosphate in trafficking and mobilization of hematopoietic stem cells.

Authors:  Linda J Bendall; Jordan Basnett
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

10.  Transforming growth factor beta 1 is an inducer of erythroid differentiation.

Authors:  G Krystal; V Lam; W Dragowska; C Takahashi; J Appel; A Gontier; A Jenkins; H Lam; L Quon; P Lansdorp
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  2 in total

1.  Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease.

Authors:  Thibaud Lefebvre; Niloofar Reihani; Raed Daher; Thierry Billette de Villemeur; Nadia Belmatoug; Christian Rose; Yves Colin-Aronovicz; Hervé Puy; Caroline Le Van Kim; Mélanie Franco; Zoubida Karim
Journal:  Haematologica       Date:  2018-01-05       Impact factor: 9.941

2.  Effects of sphingolipids overload on red blood cell properties in Gaucher disease.

Authors:  Lucie Dupuis; Caroline Chipeaux; Emmanuelle Bourdelier; Suella Martino; Nelly Reihani; Nadia Belmatoug; Thierry Billette de Villemeur; Bénédicte Hivert; Fathi Moussa; Caroline Le Van Kim; Marine de Person; Mélanie Franco
Journal:  J Cell Mol Med       Date:  2020-08-07       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.